ABOUT THIS FUND
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
PRICE
$9.02 ▲ UP 48.35% (+$73.38)—
No price history available for CNCR over this range.
HOLDINGS
TOP 20 OF 23 · 67.61% OF THE FUNDRANK STOCK WEIGHT SHARES VALUE
